Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. more
Time Frame | VRCA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -26.5% | -2.06% | -0.55% |
1-Month Return | -27.58% | -1.92% | 2.72% |
3-Month Return | -65.24% | -10.4% | 7.66% |
6-Month Return | -91.96% | -4.6% | 10.15% |
1-Year Return | -88.43% | 4.06% | 27.53% |
3-Year Return | -93.02% | 1.94% | 32.31% |
5-Year Return | -95.71% | 36.48% | 89.2% |
10-Year Return | -96.33% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 12.00M | 12.00M | 9.03M | 5.12M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":75.27,"profit":true},{"date":"2023-12-31","value":42.7,"profit":true}] |
Cost of Revenue | 257.20K | 229.00K | 472.00K | 725.00K | 746.00K | [{"date":"2019-12-31","value":34.48,"profit":true},{"date":"2020-12-31","value":30.7,"profit":true},{"date":"2021-12-31","value":63.27,"profit":true},{"date":"2022-12-31","value":97.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (257.20K) | (229.00K) | 11.53M | 8.31M | 4.38M | [{"date":"2019-12-31","value":-2.23,"profit":false},{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":72.06,"profit":true},{"date":"2023-12-31","value":37.98,"profit":true}] |
Gross Margin | - | (1.91%) | 96.07% | 91.97% | 85.44% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1.99,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.74,"profit":true},{"date":"2023-12-31","value":88.94,"profit":true}] |
Operating Expenses | 30.08M | 40.18M | 42.91M | 29.60M | 70.14M | [{"date":"2019-12-31","value":42.89,"profit":true},{"date":"2020-12-31","value":57.29,"profit":true},{"date":"2021-12-31","value":61.18,"profit":true},{"date":"2022-12-31","value":42.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (30.08M) | (40.18M) | (30.91M) | (21.30M) | (65.76M) | [{"date":"2019-12-31","value":-3008000000,"profit":false},{"date":"2020-12-31","value":-4018100000,"profit":false},{"date":"2021-12-31","value":-3090800000,"profit":false},{"date":"2022-12-31","value":-2129600000,"profit":false},{"date":"2023-12-31","value":-6575900000,"profit":false}] |
Total Non-Operating Income/Expense | 3.75M | (5.03M) | (8.34M) | (4.89M) | (659.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-134,"profit":false},{"date":"2021-12-31","value":-222.51,"profit":false},{"date":"2022-12-31","value":-130.32,"profit":false},{"date":"2023-12-31","value":-17.57,"profit":false}] |
Pre-Tax Income | (28.21M) | (42.69M) | (35.08M) | (24.49M) | (67.00M) | [{"date":"2019-12-31","value":-2820700000,"profit":false},{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false}] |
Income Taxes | (257.00K) | 2.80M | 3.82M | 3.19M | 668.11K | [{"date":"2019-12-31","value":-6.72,"profit":false},{"date":"2020-12-31","value":73.32,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.47,"profit":true},{"date":"2023-12-31","value":17.48,"profit":true}] |
Income After Taxes | (27.95M) | (45.50M) | (38.90M) | (27.68M) | (67.66M) | [{"date":"2019-12-31","value":-2795000000,"profit":false},{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3890300000,"profit":false},{"date":"2022-12-31","value":-2767800000,"profit":false},{"date":"2023-12-31","value":-6766310500,"profit":false}] |
Income From Continuous Operations | (28.21M) | (42.69M) | (35.08M) | (24.49M) | (48.31M) | [{"date":"2019-12-31","value":-2820700000,"profit":false},{"date":"2020-12-31","value":-4269400000,"profit":false},{"date":"2021-12-31","value":-3508000000,"profit":false},{"date":"2022-12-31","value":-2448700000,"profit":false},{"date":"2023-12-31","value":-4831300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (27.95M) | (45.50M) | (38.90M) | (27.68M) | (67.00M) | [{"date":"2019-12-31","value":-2795000000,"profit":false},{"date":"2020-12-31","value":-4549700000,"profit":false},{"date":"2021-12-31","value":-3890300000,"profit":false},{"date":"2022-12-31","value":-2767800000,"profit":false},{"date":"2023-12-31","value":-6699500000,"profit":false}] |
EPS (Diluted) | (1.13) | (1.71) | (1.29) | (0.79) | (1.46) | [{"date":"2019-12-31","value":-113,"profit":false},{"date":"2020-12-31","value":-171,"profit":false},{"date":"2021-12-31","value":-129,"profit":false},{"date":"2022-12-31","value":-79,"profit":false},{"date":"2023-12-31","value":-146,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VRCA | |
---|---|
Cash Ratio | 1.09 |
Current Ratio | 1.34 |
Quick Ratio | 1.22 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VRCA | |
---|---|
ROA (LTM) | -71.41% |
ROE (LTM) | -2059.89% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VRCA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.03 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VRCA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 6.88 |
P/B | 238.54 |
Price/FCF | NM |
EV/R | 9.68 |
EV/Ebitda | NM |
Verrica Pharmaceuticals Inc (VRCA) share price today is $0.636
Yes, Indians can buy shares of Verrica Pharmaceuticals Inc (VRCA) on Vested. To buy Verrica Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VRCA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Verrica Pharmaceuticals Inc (VRCA) via the Vested app. You can start investing in Verrica Pharmaceuticals Inc (VRCA) with a minimum investment of $1.
You can invest in shares of Verrica Pharmaceuticals Inc (VRCA) via Vested in three simple steps:
The 52-week high price of Verrica Pharmaceuticals Inc (VRCA) is $11.41. The 52-week low price of Verrica Pharmaceuticals Inc (VRCA) is $0.67.
The price-to-earnings (P/E) ratio of Verrica Pharmaceuticals Inc (VRCA) is
The price-to-book (P/B) ratio of Verrica Pharmaceuticals Inc (VRCA) is 238.54
The dividend yield of Verrica Pharmaceuticals Inc (VRCA) is 0.00%
The market capitalization of Verrica Pharmaceuticals Inc (VRCA) is $63.40M
The stock symbol (or ticker) of Verrica Pharmaceuticals Inc is VRCA